UTHR stock benefits from Trump-era tariffs and onshoring.
2 reports, 1 independent
Updated Jul 22
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
UTHR stock benefits from Trump-era tariffs and onshoring.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
United Therapeutics
biotech company based in Silver Spring, Maryland, United States
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Related events
- The new event concerns the impact of Trump-era tariffs and onshoring trends on Viatris.
- Barclays raised its price target for Okta, noting that AI stocks are benefiting from the onshoring trend and Trump-era tariffs.
- Elastic benefits from the trend of onshoring and tariffs associated with the Trump administration.
- Tariffs from U.S. President Trump are being implemented, creating economic challenges for British Columbia.
- Trump's tariff plan caused markets to tank, impacting Donnelley Financial Solutions.
Coverage
Newest first; wire copies grouped- Insider MonkeyUnited Therapeutics Corporation (UTHR) Completes Phase 3 Enrollment for Promising PAH Drug Ralinepag We recently published 10 Most Undervalued Pharma Stocks To Buy Now. United Therapeutics Corporatio
- Insider MonkeyUBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR) United Therapeutics Corp. (NASDAQ:UTHR) is one of the 11 best debt-free stocks to invest in right now. The company boasts a stro